Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 26, 2022- Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent- Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter- Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent- Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent- Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent- R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets- Jan 6, 2022- The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body - such as glucose, ketones, and lactate - to help people better understand their general health and take action- Abbott is the first healthcare company to headline the Consumer Electronics Show, with Chairman and CEO Robert Ford presenting alongside scientists and inventors, industry partners, influencers and people who use Abbott health tech
- Nov 15, 2021- Abbott included on DJSI for 17 consecutive years for strong environmental, social and governance (ESG) performance- Top score in the Health Care Equipment & Supplies sector reflects Abbott's 2030 Sustainability Plan focus on innovating for greater access to life-changing technologies and breaking down barriers to health equity